Abstract
The intranasal (IN) administration of lorazepam is desirable in order to maximize speed of onset and minimise carry-over sedation; however, this benzodiazepine is prone to chemical hydrolysis and poor airway retention, and thus, innovative epithelial presentation is required. The aim of this study was to understand how the in situ self-assembly of a mucoretentive delivery system, formed by the dissolution of vinyl polymer-coated microparticles in the nasal mucosa, would influence lorazepam pharmacokinetics (PK).
Original language | English |
---|---|
Pages (from-to) | 218-224 |
Journal | AAPS PharmSciTech |
Volume | 14 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2012 |